Who is sponsoring NCT06830525?

NCT06830525 is sponsored by Luis Fernandez Luque.

What drugs are being tested in NCT06830525?

Interventions in NCT06830525: ACDP® and growth hormone treatment.

What condition does NCT06830525 study?

NCT06830525 studies Growth Hormone Deficiency (GHD).

Is NCT06830525 still recruiting?

NCT06830525 is currently completed. Last updated 1 December 2025.

Last reviewed 2025-12-01 · How we verify

NCT06830525: PGTP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of a Personalized Growth Hormone Treatment Profile (PGTP) Report for Pediatric Endocrinology

Completed Last updated 1 December 2025

What this trial tests

trial testing ACDP® and growth hormone treatment in Growth Hormone Deficiency (GHD) in 40 participants. Completed in 12 November 2025.

Timeline

19 May 2025

Primary endpoint
12 November 2025

12 November 2025

Quick facts

Lead sponsor	Luis Fernandez Luque
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	19 May 2025
Primary completion	12 November 2025
Estimated completion	12 November 2025
Sites	1 location across Spain

Drugs / interventions tested

ACDP® and growth hormone treatment

Conditions studied

Growth Hormone Deficiency (GHD) — all drugs for Growth Hormone Deficiency (GHD) →

Sponsor

Luis Fernandez Luque

Who can join

Eligibility, any sex, with Growth Hormone Deficiency (GHD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn how to make growth hormone treatment more personalized for children. The main questions it aims to answer are: * How can information about treatment adherence and patient experiences help improve care? * What insights can help doctors create treatment plans that are more tailored to each child? The study will include 40 families of children who are using a connected injector device for their growth hormone treatment. These devices track how often the treatment is taken, and families will also share their experiences through surveys. The information will be used to develop a new tool, similar to tools used in diabetes care, to help doctors create better, personalized treatment plans for children with growth hormone needs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Growth Hormone Deficiency (GHD)

Currently open trials in the same condition.

NCT07412782 — REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06830525 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Luis Fernandez Luque
Last refreshed: 1 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06830525.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing